Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy Of Pomalidomide (CC-4047) In Subjects With Systemic Sclerosis with Interstitial Lung Disease

Next Previous
Trial Profile

A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy Of Pomalidomide (CC-4047) In Subjects With Systemic Sclerosis with Interstitial Lung Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Interstitial lung diseases; Systemic scleroderma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Celgene Corporation

Most Recent Events

  • 27 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
  • 01 Nov 2017 Owing to enrollment difficulty, the protocol was amended to increase the length of allowable disease duration (changed from 'onset of the first non-Raynaud SSc symptoms within 5 years prior to screening date' to 'onset of the first non-Raynaud symptoms to be within 7 years prior to screening'.)
  • 01 Nov 2017 Results published in The Journal of Rheumatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top